---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009782"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:56:05.730507+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Dyne Therapeutics reports preliminary cash of ~$1.1B as of Dec 31, 2025

## Summary
- Preliminary unaudited cash, cash equivalents and marketable securities of approximately $1.1 billion as of December 31, 2025.
- Figure is a management estimate subject to completion of financial closing procedures; no audit or review by independent accountants.
- Company also presented at J.P. Morgan Healthcare Conference on January 12, 2026; presentation content was not detailed in this filing.

## SEC filing metadata
- accession: 0001193125-26-009782
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000119312526009782/0001193125-26-009782-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000119312526009782/dyn-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009782
- JSON: https://secwatch.observer/filing/0001193125-26-009782.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009782.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.